• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Carlisle Companies Announces Leadership Appointments

    5/16/25 4:05:00 PM ET
    $CAH
    $CSL
    $SUM
    $WU
    Other Pharmaceuticals
    Health Care
    Specialty Chemicals
    Industrials
    Get the next $CAH alert in real time by email

    Carlisle Companies Incorporated (NYSE:CSL) today announced the appointment of Christopher B. Gaskill as Vice President & General Counsel for the Company. In conjunction with this appointment, Scott C. Selbach will transition to a new role as Executive Vice President, Government Relations for the Company. Mr. Selbach will also remain Secretary of the Company. Both Mr. Gaskill and Mr. Selbach will report to Chris Koch, Carlisle's Chair, President & Chief Executive Officer.

    Prior to joining Carlisle, Mr. Gaskill served as Executive Vice President, Chief Legal Officer, and Secretary at Summit Materials, Inc. (NYSE:SUM), where he was responsible for the company's global legal functions and ensuring compliance with corporate governance requirements. Prior to Summit Materials, Mr. Gaskill served as Senior Director and Counsel at The Western Union Company (NYSE:WU), Senior Counsel at Cardinal Health Inc. (NYSE:CAH) and an attorney at Simpson, Thacher & Bartlett LLP. Mr. Gaskill holds a Juris Doctor degree from the University of Virginia School of Law.

    Mr. Selbach served as Executive Vice President, Secretary & General Counsel of the Company since January 2023 and Vice President, Secretary & General Counsel from May 2018. Over his more than 30 years of employment with Carlisle, Mr. Selbach has also served as Vice President, Corporate Development and Vice President, Europe.

    Mr. Koch stated, "I am extremely pleased to announce these leadership appointments. Chris is an experienced leader with a broad range of legal and functional expertise and is a proactive, strategic business partner with a strong track record of providing insightful counsel. Scott is a multi-disciplined executive with deep roots in Carlisle who in his new role will work with legislative bodies and government agencies to promote Carlisle's innovative energy-efficient products. These appointments are further examples of how Carlisle continues to invest in exceptional talent in support of our Vision 2030 objectives."

    About Carlisle Companies Incorporated

    Carlisle Companies Incorporated is a leading supplier of innovative building envelope products and solutions for more energy efficient buildings. Through its building products businesses – Carlisle Construction Materials ("CCM") and Carlisle Weatherproofing Technologies ("CWT") – and family of leading brands, Carlisle delivers innovative, labor reducing and environmentally responsible products and solutions to customers through the Carlisle Experience. Carlisle is committed to generating superior shareholder returns and maintaining a balanced capital deployment approach, including investments in our businesses, strategic acquisitions, share repurchases and continued dividend increases. Leveraging its culture of continuous improvement as embodied in the Carlisle Operating System ("COS"), Carlisle has committed to achieving net-zero greenhouse gas emissions by 2050.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250515593954/en/

    Mehul Patel

    Vice President, Investor Relations

    Carlisle Companies Incorporated

    (310) 592 - 9668

    [email protected]

    Get the next $CAH alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CAH
    $CSL
    $SUM
    $WU

    CompanyDatePrice TargetRatingAnalyst
    Carlisle Companies Incorporated
    $CSL
    7/31/2025$395.00Buy → Hold
    Loop Capital
    Western Union Company
    $WU
    7/29/2025$7.50 → $7.00Sell
    Monness Crespi & Hardt
    Western Union Company
    $WU
    7/17/2025Hold
    Deutsche Bank
    Carlisle Companies Incorporated
    $CSL
    6/24/2025$500.00Overweight
    Analyst
    Cardinal Health Inc.
    $CAH
    6/3/2025$179.00Equal Weight → Overweight
    Wells Fargo
    Western Union Company
    $WU
    6/2/2025Perform
    Oppenheimer
    Western Union Company
    $WU
    4/24/2025$7.50Neutral → Sell
    Monness Crespi & Hardt
    Cardinal Health Inc.
    $CAH
    2/5/2025$140.00 → $150.00Hold → Buy
    Jefferies
    More analyst ratings

    $CAH
    $CSL
    $SUM
    $WU
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cardinal Health Board of Directors Approves Quarterly Dividend

    DUBLIN, Ohio, Aug. 15, 2025 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that its Board of Directors approved its quarterly dividend of $0.5107 per share, out of the Company's capital surplus. The dividend will be payable on October 15, 2025 to shareholders of record at the close of business on October 1, 2025. About Cardinal HealthCardinal Health is a distributor of pharmaceuticals and specialty products; a global manufacturer and distributor of medical and laboratory products; a supplier of home-health and direct-to-patient products and services; an operator o

    8/15/25 4:40:00 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    Carlisle Companies Announces Pricing of Senior Notes Offering

    Carlisle Companies Incorporated (NYSE:CSL) today announced that it has priced a public offering of $500 million in aggregate principal amount of its 5.250% notes due September 15, 2035, and $500 million in aggregate principal amount of its 5.550% notes due September 15, 2040 (collectively, the "Notes"). Carlisle expects the offering to close on August 20, 2025, subject to customary closing conditions. Carlisle intends to use the net proceeds from the offering for general corporate purposes, which may include repayment of debt, additions to working capital, capital expenditures, investments in its subsidiaries, acquisitions, investments in third parties or the repurchase, redemption or ret

    8/13/25 5:01:00 PM ET
    $CSL
    Specialty Chemicals
    Industrials

    Carlisle Companies Publishes 2024 Corporate Sustainability Report

    Carlisle Companies Incorporated (NYSE:CSL) today published its 2024 Corporate Sustainability Report, highlighting progress toward Carlisle's sustainability goals through its legacy of innovation in sustainability and culture of continuous improvement fostered through the Carlisle Operating System. "In 2024, we entered the next phase of our sustainability roadmap: generating shareholder value through sustainability," said Chris Koch, Chair, President and Chief Executive Officer. "I'm proud of the progress we made against our three-pillar sustainability strategy, and the impact our people made last year by manufacturing products that have the potential to save our customers $20 billion over

    8/13/25 4:05:00 PM ET
    $CSL
    Specialty Chemicals
    Industrials

    $CAH
    $CSL
    $SUM
    $WU
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Carlisle Cos downgraded by Loop Capital with a new price target

    Loop Capital downgraded Carlisle Cos from Buy to Hold and set a new price target of $395.00

    7/31/25 7:57:21 AM ET
    $CSL
    Specialty Chemicals
    Industrials

    Monness Crespi & Hardt reiterated coverage on Western Union with a new price target

    Monness Crespi & Hardt reiterated coverage of Western Union with a rating of Sell and set a new price target of $7.00 from $7.50 previously

    7/29/25 7:44:06 AM ET
    $WU
    Real Estate

    Deutsche Bank resumed coverage on Western Union

    Deutsche Bank resumed coverage of Western Union with a rating of Hold

    7/17/25 9:22:37 AM ET
    $WU
    Real Estate

    $CAH
    $CSL
    $SUM
    $WU
    SEC Filings

    View All

    SEC Form 8-K filed by Cardinal Health Inc.

    8-K - CARDINAL HEALTH INC (0000721371) (Filer)

    8/14/25 5:06:21 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Western Union Company

    SCHEDULE 13G/A - Western Union CO (0001365135) (Subject)

    8/14/25 1:07:20 PM ET
    $WU
    Real Estate

    Western Union Company filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - Western Union CO (0001365135) (Filer)

    8/14/25 7:54:15 AM ET
    $WU
    Real Estate

    $CAH
    $CSL
    $SUM
    $WU
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Murphy Timothy P. was granted 15,625 shares and bought $128,499 worth of shares (10,000 units at $12.85), increasing direct ownership by 84% to 56,205 units (SEC Form 4)

    4 - Western Union CO (0001365135) (Issuer)

    2/28/24 9:43:15 PM ET
    $WU
    Real Estate

    $CAH
    $CSL
    $SUM
    $WU
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Information Officer Greene Michelle D. was granted 16,362 shares, increasing direct ownership by 88% to 34,968 units (SEC Form 4)

    4 - CARDINAL HEALTH INC (0000721371) (Issuer)

    8/12/25 4:28:58 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    CEO, PSS Segment Weitzman Deborah was granted 39,100 shares, increasing direct ownership by 80% to 88,229 units (SEC Form 4)

    4 - CARDINAL HEALTH INC (0000721371) (Issuer)

    8/12/25 4:19:07 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    Chief Human Resources Officer Snow Ola M was granted 31,813 shares, increasing direct ownership by 135% to 55,351 units (SEC Form 4)

    4 - CARDINAL HEALTH INC (0000721371) (Issuer)

    8/12/25 4:17:58 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    $CAH
    $CSL
    $SUM
    $WU
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Summit Materials Inc.

    SC 13D/A - Summit Materials, Inc. (0001621563) (Subject)

    11/25/24 9:19:55 AM ET
    $SUM
    Mining & Quarrying of Nonmetallic Minerals (No Fuels)
    Industrials

    Amendment: SEC Form SC 13G/A filed by Summit Materials Inc.

    SC 13G/A - Summit Materials, Inc. (0001621563) (Subject)

    11/14/24 1:22:36 PM ET
    $SUM
    Mining & Quarrying of Nonmetallic Minerals (No Fuels)
    Industrials

    SEC Form SC 13G filed by Western Union Company

    SC 13G - Western Union CO (0001365135) (Subject)

    11/14/24 1:22:35 PM ET
    $WU
    Real Estate

    $CAH
    $CSL
    $SUM
    $WU
    Leadership Updates

    Live Leadership Updates

    View All

    After Major Oncology Conference, All Eyes Turn to Industry Innovation

    USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 12, 2025 /PRNewswire/ -- After the close of the world's largest cancer conference (the 2025 American Society of Clinical Oncology annual meeting), doctors, scientists, and researchers are optimistic, especially in the fields of immunotherapy, Car T-cell therapy, liquid biopsies, breast cancer, AI, and even exercise. However, with reports coming out that the current US administration could drastically reduce funding of the National Cancer Institute (NCI) by nearly 40%, the market is looking towards the private sector to pick up the slack and continue to make advancements in cancer treatment. For inv

    6/12/25 9:00:00 AM ET
    $CAH
    $CTOR
    $CTXR
    Other Pharmaceuticals
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Carlisle Companies Announces Leadership Appointments

    Carlisle Companies Incorporated (NYSE:CSL) today announced the appointment of Christopher B. Gaskill as Vice President & General Counsel for the Company. In conjunction with this appointment, Scott C. Selbach will transition to a new role as Executive Vice President, Government Relations for the Company. Mr. Selbach will also remain Secretary of the Company. Both Mr. Gaskill and Mr. Selbach will report to Chris Koch, Carlisle's Chair, President & Chief Executive Officer. Prior to joining Carlisle, Mr. Gaskill served as Executive Vice President, Chief Legal Officer, and Secretary at Summit Materials, Inc. (NYSE:SUM), where he was responsible for the company's global legal functions and ensu

    5/16/25 4:05:00 PM ET
    $CAH
    $CSL
    $SUM
    Other Pharmaceuticals
    Health Care
    Specialty Chemicals
    Industrials

    Robert Musslewhite and Sudhakar Ramakrishna to join Cardinal Health Board of Directors

    DUBLIN, Ohio, March 10, 2025 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that its Board of Directors has elected Robert Musslewhite, former Chief Executive Officer of Definitive Healthcare Corp., and Sudhakar Ramakrishna, President and Chief Executive Officer of SolarWinds Corporation, as independent directors, effective March 7, 2025. With more than 20 years of leadership experience, including serving as CEO for two publicly traded companies, Mr. Musslewhite brings to the board unique expertise in advanced analytics, data, and technology across the healthcare e

    3/10/25 6:45:00 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    $CAH
    $CSL
    $SUM
    $WU
    Financials

    Live finance-specific insights

    View All

    Cardinal Health Board of Directors Approves Quarterly Dividend

    DUBLIN, Ohio, Aug. 15, 2025 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that its Board of Directors approved its quarterly dividend of $0.5107 per share, out of the Company's capital surplus. The dividend will be payable on October 15, 2025 to shareholders of record at the close of business on October 1, 2025. About Cardinal HealthCardinal Health is a distributor of pharmaceuticals and specialty products; a global manufacturer and distributor of medical and laboratory products; a supplier of home-health and direct-to-patient products and services; an operator o

    8/15/25 4:40:00 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    Carlisle Companies Publishes 2024 Corporate Sustainability Report

    Carlisle Companies Incorporated (NYSE:CSL) today published its 2024 Corporate Sustainability Report, highlighting progress toward Carlisle's sustainability goals through its legacy of innovation in sustainability and culture of continuous improvement fostered through the Carlisle Operating System. "In 2024, we entered the next phase of our sustainability roadmap: generating shareholder value through sustainability," said Chris Koch, Chair, President and Chief Executive Officer. "I'm proud of the progress we made against our three-pillar sustainability strategy, and the impact our people made last year by manufacturing products that have the potential to save our customers $20 billion over

    8/13/25 4:05:00 PM ET
    $CSL
    Specialty Chemicals
    Industrials

    Cardinal Health Reports Fourth Quarter and Fiscal Year 2025 Results and Raises Fiscal Year 2026 Guidance

    Fourth quarter revenue was relatively flat at $60.2 billion; revenue increased 21% excluding the impact of a previously communicated contract expirationFourth quarter GAAP1 operating earnings were $428 million and GAAP diluted EPS was $1.00Fourth quarter non-GAAP operating earnings increased 19% to $719 million and non-GAAP diluted EPS increased 13% to $2.08Fiscal Year 2025 adjusted free cash flow was $2.5 billionFiscal year 2026 non-GAAP EPS guidance2 raised to $9.30 to $9.50, from $9.10 to $9.30Company announces the acquisition of Solaris Health, the country's leading urology MSODUBLIN, Ohio, Aug. 12, 2025 /PRNewswire/ -- Cardinal Health (NYSE:CAH) today reported fourth quarter fiscal year

    8/12/25 6:55:00 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care